Holen Sie sich die Stockscreener-App
135.51
2.81%
-3.9161
Schlusskurs vom Vortag:
$139.43
Offen:
$138.77
24-Stunden-Volumen:
149.19K
Relative Volume:
0.48
Marktkapitalisierung:
$4.69B
Einnahmen:
$290.51M
Nettoeinkommen (Verlust:
$89.16M
KGV:
45.32
EPS:
2.99
Netto-Cashflow:
$119.18M
1W Leistung:
-2.84%
1M Leistung:
-17.87%
6M Leistung:
-26.44%
1J Leistung:
-12.47%
1-Tages-Spanne:
$133.24
$138.77
1-Wochen-Bereich:
$131.71
$141.37
52-Wochen-Spanne:
$131.71
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
Firmenname
Krystal Biotech Inc
Sektor
Branche
Telefon
(412) 586-5830
Adresse
2100 WHARTON STREET, PITTSBURGH, PA
Vergleichen Sie KRYS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
135.33 | 4.69B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.70 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.11 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
540.02 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
265.18 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
223.32 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Eingeleitet | Jefferies | Buy |
| 2024-08-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Eingeleitet | Citigroup | Buy |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2023-02-28 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-18 | Eingeleitet | BofA Securities | Buy |
| 2021-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-04 | Eingeleitet | Evercore ISI | Outperform |
| 2019-09-24 | Eingeleitet | Goldman | Neutral |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-24 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-30 | Eingeleitet | Guggenheim | Buy |
| 2018-09-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
Krystal Biotech's (NASDAQ:KRYS) Solid Earnings Have Been Accounted For Conservatively - Yahoo Finance
Krystal Biotech Expands Gene Therapy Platform - TipRanks
How the (KRYS) price action is used to our Advantage - news.stocktradersdaily.com
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Krystal Biotech, Inc. (KRYS): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
H.C. Wainwright maintains Buy on Krystal Biotech shares - Investing.com Australia
Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates - MSN
Krystal Biotech "insulated" by domestic manufacturingPittsburgh Business Times - The Business Journals
Krystal Biotech (KRYS) Price Target Lowered by Guggenheim | KRYS Stock News - GuruFocus
H.C. Wainwright maintains Buy on Krystal Biotech shares By Investing.com - Investing.com Canada
Krystal Biotech (KRYS) Faces Hurdles After Lowered Price Target - GuruFocus
Krystal Biotech (KRYS) Faces Hurdles After Lowered Price Target | KRYS Stock News - GuruFocus
Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2025 Earnings Call Transcript - Insider Monkey
Krystal Biotech to Present at BofA Securities 2025 Health Care Conference - The Manila Times
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down - MSN
Krystal Biotech (KRYS) Maintains Buy Rating and Price Target | KRYS Stock News - GuruFocus
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Call Highlights: Rec - GuruFocus
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Krystal Biotech Reports Strong Q1 2025 Results - TipRanks
Decoding Krystal Biotech Inc (KRYS): A Strategic SWOT Insight - GuruFocus
Krystal Biotech outlines 2025 global launch strategy with $88.2M Q1 VYJUVEK revenue - MSN
Krystal Biotech’s Earnings Call Highlights Growth and Expansion - TipRanks
Earnings call transcript: Krystal Biotech misses Q1 2025 EPS forecast, stock drops 14% - Investing.com
Krystal Biotech (KRYS) Receives Reiterated Buy Rating and Maintained Price Target | KRYS Stock News - GuruFocus
Krystal Biotech Q1 2025 slides: VYJUVEK revenue up 95% YoY despite sequential dip By Investing.com - Investing.com South Africa
Krystal Biotech is Now Oversold (KRYS) - Nasdaq
Krystal Biotech Q1 2025 slides: VYJUVEK revenue up 95% YoY despite sequential dip - Investing.com India
Krystal Biotech shares tumble as Q1 results miss expectations By Investing.com - Investing.com Nigeria
Krystal Biotech shares tumble as Q1 results miss expectations - Investing.com
Krystal Biotech Q1 2025 Earnings: EPS of $1.24 and Revenue of $8 - GuruFocus
Krystal Biotech (KRYS) Reports Q1 Revenue Below Expectations Ami - GuruFocus
KRYSTAL BIOTECH Earnings Results: $KRYS Reports Quarterly Earnings - Nasdaq
Krystal Biotech's Q1 Earnings, Revenue Rise - marketscreener.com
Krystal Biotech, Inc. SEC 10-Q Report - TradingView
Krystal Biotech Announces First Quarter 2025 Financial and Operating Results - The Manila Times
Krystal Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings Flash (KRYS) Krystal Biotech Reports Q1 Revenue $88.2M, vs. FactSet Est of $96.2M - marketscreener.com
Krystal Biotech Presents Promising Gene Therapy at ARVO - TipRanks
Krystal Biotech Q1 2025 Earnings Preview - MSN
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Krystal Biotech (KRYS) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Chardan Capital Forecasts Krystal Biotech FY2025 Earnings - Defense World
Where are the Opportunities in (KRYS) - news.stocktradersdaily.com
Commit To Purchase Krystal Biotech At $150, Earn 16.3% Annualized Using Options - Nasdaq
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Krystal Biotech shares rise as H.C. Wainwright lifts price target By Investing.com - Investing.com Canada
Krystal Biotech (NASDAQ:KRYS) Given New $240.00 Price Target at HC Wainwright - Defense World
Krystal Biotech’s VYJUVEK gets European approval for DEB treatment - Investing.com
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Benzinga
Finanzdaten der Krystal Biotech Inc-Aktie (KRYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.19%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):